Marupuru Srujitha, Arku Daniel, Campbell Ashley M, Slack Marion K, Lee Jeannie K
R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
J Clin Med. 2022 Aug 31;11(17):5138. doi: 10.3390/jcm11175138.
To investigate the efficacy of melatonin and/or ramelteon reporting sleep outcomes for older adults with chronic insomnia, a systematic review and a meta-analysis of PubMed, EMBASE, Cochrane library, International Pharmaceutical Abstracts, PsycINFO, science citation index, center for reviews and dissemination, CINAHL, grey literature and relevant sleep journal searches were conducted from 1 January 1990 to 20 June 2021. Randomized controlled trials and other comparative studies with melatonin and/or ramelteon use among older patients with chronic insomnia were included. Funnel plot and Egger's test was used to determine publication bias. A forest plot was constructed to obtain a pooled standardized mean difference using either a fixed or random effects model for each of the two broad categories of sleep outcomes: objective and subjective. Of 5247 studies identified, 17 studies met the inclusion criteria for MA. Study sample size ranged from 10 to 829 with the mean age ≥55 years. There were significant improvements in total sleep time (objective), sleep latency and sleep quality (objective and subjective) for melatonin and/or ramelteon users compared with placebo. Sleep efficiency was not significantly different. The effects of these agents are modest but with limited safe treatment options for insomnia in older adults, these could be the drugs of choice.
为了研究褪黑素和/或雷美替胺对患有慢性失眠的老年人睡眠结果的疗效,我们对1990年1月1日至2021年6月20日期间的PubMed、EMBASE、Cochrane图书馆、国际药学文摘、PsycINFO、科学引文索引、综述与传播中心、CINAHL、灰色文献以及相关睡眠期刊进行了系统综述和荟萃分析。纳入了在患有慢性失眠的老年患者中使用褪黑素和/或雷美替胺的随机对照试验和其他比较研究。采用漏斗图和Egger检验来确定发表偏倚。构建森林图,使用固定效应模型或随机效应模型,针对客观和主观这两大类睡眠结果中的每一项,获得合并的标准化平均差。在识别出的5247项研究中,有17项研究符合荟萃分析的纳入标准。研究样本量从10到829不等,平均年龄≥55岁。与安慰剂相比,使用褪黑素和/或雷美替胺的患者在总睡眠时间(客观)、睡眠潜伏期和睡眠质量(客观和主观)方面有显著改善。睡眠效率没有显著差异。这些药物的效果虽不显著,但鉴于老年人失眠的安全治疗选择有限,它们可能是首选药物。